Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A Veterinary Radiation Therapy Oncology Group pilot study

Veterinary Radiology and Ultrasound

Volumn 45, Issue 5, 2004, Pages 466-470

  LeBlanc, Amy K ^a,d   LaDue, Tracy A ^a   Turrel, Jane M ^b   Klein, Mary Kay ^c  

^a Florida Veterinary Specialists   (United States)

^b Veterinary Oncology Specialties   (United States)

^c SW Veterinary Specialty Center ^*  (United States)

^d UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Gemcitabine; Radiosensitizer; Radiotherapy; Veterinary

Indexed keywords

GEMCITABINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAT; CONTROLLED STUDY; DOG; HEAD AND NECK CARCINOMA; NONHUMAN; ONCOLOGY; PILOT STUDY; RADIATION DOSE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CAT DISEASES; CATS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOG DISEASES; DOGS; FEMALE; HEAD AND NECK NEOPLASMS; MALE; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 7244221409     PISSN: 10588183     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1740-8261.2004.04080.x     Document Type: Article

References (32)

1. Rocha Lima C, Urbanic J, Lal A. Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol 2001;28:34-43.
2. Lawrence TS, Blackstock A, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Rad Oncol 2003;13:13-21.
3. Crane C, Wolff R, Abbruzzese JL. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables in influencing the therapeutic index. Semin Oncol 2001;28:25-33.
4. Braakhuis BJM, Ruiz van Haperen VWT, Welters MJP, et al. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995;31A:2335-2340.
5. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-2212.
6. Hall EJ. Radiobiology for the radiologist, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.
7. Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2′,2′- difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-3223.
8. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-114.
9. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867-872.
10. Latz D, Fleckenstein K, Eble M, et al. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998;41:875-882.
11. Boven E, Schipper H, Erkelens CAM, et al. The influence of the schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer. Br J Cancer 1993;68:52-56.
12. Guchelaar HJ, Richel DJ, van Knapen A. Clinical, toxicological, and pharmacological aspects of gemcitabine. Cancer Treatment Rev 1996;22:15-31.
13. Heinemann V, Xu Y, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992;52:533-539.
14. Boyce KL, Kitchell BE. Gemcitabine single-agent for the treatment of advanced cancer in the dog and cat; a pilot study. Proceedings of the 18th Annual Meeting of the Veterinary Cancer Society, 1998.
15. Jones PD, Kitchell BE, Losonosky JM. Gemcitabine as a radiosensitizer for non-resectable feline oral squamous cell carcinoma. Proceedings of the 21st Annual Meeting of the Veterinary Cancer Society, 2001.
16. Kisseberth WC, Kosarek CE, Couto CG. Phase I evaluation of gemcitabine (Gemzar) in tumor bearing dogs. Proceedings of the 22nd Annual Meeting of the Veterinary Cancer Society, 2002.
17. Marconato L, Lindner DL, Suslak-Brown L, et al. A phase I clinical trial of high dose gemcitabine in 33 dogs with transitional cell carcinoma. Proceedings of the 22nd Annual Meeting of the Veterinary Cancer Society, 2002.
18. Evans SM, LaCreta F, Helfand SC. Technique, pharmacokinetics, toxicity and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1991;20:703-708.
19. Simon D, Ruslander D, Rassnick K. Combination of orthovoltage radiotherapy and concurrent low-dose doxorubicin for incompletely excised soft tissue sarcomas in 41 dogs. Proceedings of the 20th Annual Meeting of the Veterinary Cancer Society, 2000.
20. Theon AP, Simonson E, Madewell BR. Irradiation and carboplatin chemotherapy for treatment of advanced canine intranasal carcinomas. Proceedings of the Annual Scientific Meeting of the ACVR, 2002.
21. MacEwen E, Withrow S, Patnaik A. Nasal tumors in the dog: retrospective evaluation of diagnosis, prognosis and treatment. J Am Vet Med Assoc 1977;170:45-48.
22. Theon AP, Madewell BR, Harb MF, et al. Megavoltage irradiation of neoplasms of the nasal and paranasal cavities in 77 dogs. J Am Vet Med Assoc 1993;202:1469-1475.
23. Adams WM, Miller PE, Vail DM, et al. An accelerated technique for irradiation of malignant canine nasal and paranasal sinus tumors. Vet Radiol Ultrasound 1998;39:475-481.
24. Postorino-Reeves NC, Turrel JM, Withrow SJ. Oral squamous cell carcinoma in the cat. J Am Vet Med Assoc 1993;202:438-441.
25. Hutson CA, Willauer CC, Walder EJ, et al. Treatment of mandibular squamous cell carcinoma in cats by use of mandibulectomy and radiotherapy: 7 cases (1987-1989). J Am Vet Med Assoc 1992;201:777-781.
26. Ogilvie G, Moore A, Obradovich J. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. J Am Vet Med Assoc 1993;202:1839-1844.
27. Hahn K, Knapp D, Richardson R. Clinical response of nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs. J Am Vet Med Assoc 1992;200:355-357.
28. Fox LE, Rosenthal RC, King RR, et al. Use of cis-bis-neodecanoato-trans- R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. Am J Vet Res 2000;61:791-795.
29. Owen L. Classification of tumors in domestic animals, 1st ed. Geneva: World Health Organization, 1980.
30. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorperation study. J Clin Oncol 2001;19:792-799.
31. Hahn K, Richardson R. Cancer chemotherapy: a veterinary handbook, 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1995.
32. LaDue TA, Klein MK. Toxicity criteria of the veterinary radiation therapy oncology group. Vet Radiol Ultrasound 2001;42:475-476.